Close Menu

NEW YORK — 4basebio, formerly Expedeon, said on Tuesday that it will buy back 2 million of its treasury shares, representing approximately 4 percent of the company's current share capital.

4basebio said that it will price the treasury shares between €1.60 to €1.85 ($1.77 to $2.05) apiece, with the final purchase price to be determined after the expiry of the offer's acceptance period. The Heidelberg, Germany-based firm said that it is considering retaining the shares in treasury, potentially in order to help fund a future company or equity acquisition.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.